Ohr Pharmaceutical to Present at ARVO Annual Meeting on May 6, 2012
MAY 3, 2012 - 08:30 ET
FOR: OHR PHARMACEUTICAL INC.
NEW YORK, NY--(Marketwire - May 3, 2012) - Ohr Pharmaceutical Inc. (
The schedule and details of the presentation on the therapeutic potential of Squalamine eye drops for the treatment of wet-AMD at ARVO are as follows:
Abstract title: "A Novel Eye Drop Formulation of Squalamine For Exudative AMD: Evaluation Of Ocular Distribution And Ocular Safety In Rabbits"
Session Number: 114
Session Title: AMD: New Drugs, Delivery Systems and Mechanisms
Session Time: Sunday, May 6, 2012, 8:30 AM - 10:15 AM
Location: Hall B/C
Program #/Board #: 457/D1134
The presenting author will be Dr. Irach B. Taraporewala, Ph.D., CEO of Ohr Pharmaceutical, who will be on hand to answer any questions.
Squalamine is an anti-angiogenic small molecule with a novel intracellular mechanism of action, that counteracts not only Vascular Endothelial Growth Factor ("VEGF") but also other angiogenic growth factors such as Platelet Derived Growth Factor ("PDGF") with high potency at nanomolar concentrations. Recent clinical evidence has shown PDGF to be an additional key target for the treatment of wet-AMD. Using the intravenous formulation in over 250 patients in Phase 1 and Phase 2 trials for the treatment of wet-AMD, Squalamine demonstrated favorable biologic effect and maintained and improved visual acuity outcomes, with both early and advanced lesions responding. The previous IV formulation had been awarded fast track status and a Special Protocol Assessment for a phase III registration study from the U.S. Food and Drug Administration ("FDA"). Ohr Pharmaceutical has developed a novel eye drop formulation of squalamine for the treatment of wet-AMD designed for self-administration which may provide several potential advantages over the FDA approved current standards of care, Roche/Genentech's Lucentis® and Regeneron's Eylea®, which require intravitreal injections directly into the eye. Preclinical testing has demonstrated that the eye drop formulation is both safe to ocular tissues and achieves in excess of target anti-angiogenic concentrations in the tissues of the back of the eye.
About Ohr Pharmaceutical Inc.
Ohr Pharmaceutical Inc. (
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.
Tel: (877) 215-4813